<p>PC12 cells were treated with L-DOPA at different concentration for 3 days, and CD39 protein expression was measured by immunofluorescence staining (A) and western blot assay (B). L-DOPA treatment resulted in an increase in CD39 expression when compared with un-treated group and peaked at 10 µM L-DOPA (C). *P<0.05 vs. untreated group. #P>0.05 vs. untreated group.</p
We investigated the effects of dopaminergic stimulation on anti-apoptotic protein Bcl-2, pro-apoptot...
<p>A, Effects of pre-DOX+LMB treatment on the protein expression of p53, phospho-p53 (Ser15), phosph...
Dopamine (DA) is a neurotransmitter in the central and peripheral nervous system, which can be eithe...
<p>PC12 cells were treated with L-DOPA at different concentrations for 3 days, and PCREB protein exp...
<p>PC12 cells were seeded into 96-well plates (5×10<sup>3</sup>/well; 200 µl/well) and divided into ...
This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal cell death u...
<p>Rats were treated with L-DOPA at different concentrations (0, 30 60 and 120 mg/kg) once daily for...
OBJECTIVE: This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal c...
<p>Rats were treated with L-DOPA once daily for 7 days and the brains were quickly harvested for imm...
<p>PC12 cells were treated with 0, 1, 5, 10, 20, 30, 40 and 50 µmol/L L-DOPA for 3 days with or with...
Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson’s disease. T...
<p>A) L-DOPA increased H3S28p and H3K27me3S8p in the lesioned striatum that progressively decreased ...
Dopamine receptor agonists and L-dihydroxyphenylalanine (L-DOPA) counteract dopamine loss in the str...
Dopamine receptor agonists and L-dihydroxyphenylalanine (L-DOPA) counteract dopamine loss in the str...
(A) Immunoblots showing comparable levels of Cdk5 and p35 in H1666 and H520 cells. However, H520 cel...
We investigated the effects of dopaminergic stimulation on anti-apoptotic protein Bcl-2, pro-apoptot...
<p>A, Effects of pre-DOX+LMB treatment on the protein expression of p53, phospho-p53 (Ser15), phosph...
Dopamine (DA) is a neurotransmitter in the central and peripheral nervous system, which can be eithe...
<p>PC12 cells were treated with L-DOPA at different concentrations for 3 days, and PCREB protein exp...
<p>PC12 cells were seeded into 96-well plates (5×10<sup>3</sup>/well; 200 µl/well) and divided into ...
This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal cell death u...
<p>Rats were treated with L-DOPA at different concentrations (0, 30 60 and 120 mg/kg) once daily for...
OBJECTIVE: This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal c...
<p>Rats were treated with L-DOPA once daily for 7 days and the brains were quickly harvested for imm...
<p>PC12 cells were treated with 0, 1, 5, 10, 20, 30, 40 and 50 µmol/L L-DOPA for 3 days with or with...
Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson’s disease. T...
<p>A) L-DOPA increased H3S28p and H3K27me3S8p in the lesioned striatum that progressively decreased ...
Dopamine receptor agonists and L-dihydroxyphenylalanine (L-DOPA) counteract dopamine loss in the str...
Dopamine receptor agonists and L-dihydroxyphenylalanine (L-DOPA) counteract dopamine loss in the str...
(A) Immunoblots showing comparable levels of Cdk5 and p35 in H1666 and H520 cells. However, H520 cel...
We investigated the effects of dopaminergic stimulation on anti-apoptotic protein Bcl-2, pro-apoptot...
<p>A, Effects of pre-DOX+LMB treatment on the protein expression of p53, phospho-p53 (Ser15), phosph...
Dopamine (DA) is a neurotransmitter in the central and peripheral nervous system, which can be eithe...